Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | CNR2 | P34972 | 3/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | PLAU | P00749 | 1/20 | 0.40 |
| ▸ | HPN | P05981 | 1/20 | 0.40 |
| ▸ | METAP2 | P50579 | 1/20 | 0.40 |
| ▸ | METAP1 | P53582 | 1/20 | 0.40 |
| ▸ | DHODH | Q02127 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2076249 | 1.00 | ALDH1A1 (0.51) | ALDH1A1CNR2BACE1BCHEACHE | |
| SCHEMBL2076247 | 1.00 | ALDH1A1 (0.51) | ALDH1A1CNR2BACE1BCHEACHE | |
| SCHEMBL19321714 | 0.93 | ALDH1A1 (0.42) | ALDH1A1CNR2CA12CA9DHODH | |
| SCHEMBL17593248 | 0.87 | EGFR (0.43) | ALDH1A1CYP1A2CYP3A4LMNADHODH | |
| SCHEMBL17593249 | 0.87 | EGFR (0.43) | ALDH1A1CYP1A2CYP3A4LMNADHODH | |
| SCHEMBL17593246 | 0.87 | EGFR (0.43) | ALDH1A1CYP1A2CYP3A4LMNADHODH | |
| SCHEMBL7925816 | 0.86 | GAA (0.49) | ALDH1A1BCHEACHECA12CYP1A2 | |
| SCHEMBL7933300 | 0.86 | GAA (0.49) | ALDH1A1BCHEACHECA12CYP1A2 | |
| SCHEMBL21378598 | 0.86 | GAA (0.49) | ALDH1A1BCHEACHECA12CYP1A2 | |
| SCHEMBL4596569 | 0.86 | ALDH1A1 (0.53) | ALDH1A1CNR2BCHEACHECA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897793-B2 | Forming latanoprost; alkylation; reductive desulfurization | INSTYTUT FARMACEUTYCZNY (PL) | 2011-03-01 | — | — | US | disclosed |
| US-20090093651-A1 | PROCESS FOR PREPARATION OF 13,14-DIHYDRO-PGF2 ALPHA DERIVATIVES | INSTYTUT FARMACEUTYCZNY (PL) | 2009-04-09 | — | — | US | disclosed |
| US-20080207926-A1 | PROCESS FOR PREPARATION OF 13,14-DIHYDRO-PGF2 ALPHA DERIVATIVES | INSTYTUT FARMACEUTYCZNY (PL) | 2008-08-28 | — | — | US | disclosed |
| EP-1891005-A2 | PROCESS FOR PREPARATION OF 13,14-DIHYDRO-PGF2 ALPHA DERIVATIVES | INSTYTUT FARMACEUTYCZNY (PL) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006112742-A2 | PROCESS FOR PREPARATION OF 13,14-DIHYDRO-PGF2α DERIVATIVES | INSTYTUT FARMACEUTYCZNY (PL) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093651-A1 | PROCESS FOR PREPARATION OF 13,14-DIHYDRO-PGF2 ALPHA DERIVATIVES | PTGIS, PTGS2, PTGES2 | ALDH1A1 599/4885CNR2 200/4885BACE1 3496/4885 |
| US-20080207926-A1 | PROCESS FOR PREPARATION OF 13,14-DIHYDRO-PGF2 ALPHA DERIVATIVES | PTGIS, PTGS2, PTGES2 | ALDH1A1 599/4885CNR2 200/4885BACE1 3496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.